Protalix BioTherapeutics, Inc.

PLXAMEXHealthcare● Active

$1.96

$-0.03(-1.51%)

Market Cap$157920418

P/E Ratio—

52W High$3.19

52W Low$1.32

Avg Volume867K

Open$1.97

Beta0.01

Overview

Protalix BioTherapeutics, Inc. (PLX) Free Cash Flow & Analysis

Annual & trailing free cash flow, FCF margin, YoY change, valuation ratios, and peer context.

PLX · free cash flow · updated Jun 9, 2026

Core FCF metrics

PLX · FCF · TTM · margin & CAGR

Free cash flow was −$13.6M for FY2025 (fiscal year ending 2025-12-31), down 284.4% year-over-year The FCF margin was -25.8%.

FY2025 Free Cash Flow−$13.6M▼ -284.4% YoY

Trailing 12M (TTM)$14.6MTrailing 4Q sum · TTM positive vs latest FY negative

FCF Margin-25.8%−$13.6M ÷ revenue

3-Year CAGRN/AN/A — contains negative FCF

5-Year CAGRN/AN/A — contains negative FCF

FormulaFCF = Operating Cash Flow − Capital ExpendituresTTM = trailing 4 quarters sumCAGR → N/A if either endpoint ≤ 0

Source: FMP /cash-flow-statement · SEC 10-K / 10-Q · USDUpdated: Jun 9, 2026

Annual free cash flow history

FCF ($B, upper) · YoY Growth % (lower)

Positive FCFNegative FCF

Free Cash Flow

YoY Growth %

Annual free cash flow data

PLX · free cash flow history · annual / quarterly

Fiscal YearOperating CFCapExFree Cash FlowYoY ChangeFCF Margin

FY2025Latest−$12.0M(2M)−$13.6M▼ 284.4%-25.8%

FY2024$8.7M(1M)$7.4M▲ +399.6%13.8%

FY2023−$1.3M(1M)−$2.5M▲ +90.4%-3.8%

FY2022−$25.0M(1M)−$25.6M▼ 118.2%-53.8%

FY2021−$10.3M(1M)−$11.7M▲ +56.1%-30.6%

FCF = Operating Cash Flow − Capital Expenditures · CapEx shown as (negative) · Source: SEC filings via FMP

FCF valuation metrics

PLX · P/FCF · FCF yield · FCF per share

Protalix BioTherapeutics, Inc. (PLX) trades at a FCF yield of 9.27% and a price-to-free-cash-flow ratio of 10.3x. FCF per share stands at $0.19, calculated using trailing twelve-month FCF divided by basic weighted-average shares outstanding.

FCF Yield (TTM)

9.27%

Free Cash Flow ÷ Market Cap

per FMP freeCashFlowYieldTTM definition

FCF per Share (TTM)

$0.19

TTM FCF ÷ Shares Outstanding

Price / FCF

x10.3

Share Price ÷ FCF per Share

EV / FCF (TTM)

x8.5

Enterprise Value basis

Source: FMP /key-metrics-ttm · /cash-flow-statement Q · /income-statementFY2025 · 2025-12-31

Cash flow statement summary

PLX · cash flow statement · operating / investing / financing

For FY2025, Protalix BioTherapeutics, Inc. generated −$12.0M in operating cash flow and spent 2M in capital expenditures, yielding −$13.6M in free cash flow.

Operating Activities

−$12.0M

Cash from core business operations

2025-12-31

Investing Activities

−$2.4M

CapEx, acquisitions & investments

2025-12-31

Financing Activities

+$9.3M

Buybacks, dividends & debt

2025-12-31

FCF FormulaOperating CF (−$12.0M) − |CapEx| (2M) = FCF (−$13.6M)

For the complete Operating / Investing / Financing line-item breakdown:

View Full Cash Flow Statement →

Free cash flow vs peers (Healthcare)

PLX vs peers · FCF

#CompanyFree Cash FlowYoYFCF MarginRelative

Protalix BioTherapeutics, Inc.YOU

PLX

−$13.6M-284.4%-25.8%

Loss

UnitedHealth Group Incorporated

UNH

$16.07B-22.4%3.6%

82%

Eli Lilly and Company

LLY

$8.97B+2065.6%13.8%

46%

Healthcare · Sorted by FCF · FMP /cash-flow-statementFull FCF Rankings →

About Free Cash Flow & Methodology

Protalix BioTherapeutics, Inc. (PLX) reported free cash flow of −$13.6M for FY2025 (fiscal year ending 2025-12-31), down 284.4% year-over-year. The FCF margin was -25.8%.

Based on available data, Protalix BioTherapeutics, Inc. has maintained positive free cash flow for at least 1 fiscal year(s). FCF peaked at $7.4M in FY2024.

Protalix BioTherapeutics, Inc.'s FCF yield is 9.27% and price-to-FCF ratio is 10.3x for FY2025, based on the latest available data.

Data sourced from FMP /cash-flow-statement · SEC 10-K / 10-Q · USD.

Q&A and summaries align with SEC 10-K/10-Q cash flow disclosures and FMP /cash-flow-statement where noted.

Revenue Financial statements Net income Earnings Forecast Price history Market cap Cash on hand P/E ratio

Frequently asked questions

PLX free cash flow · 8 questions

Protalix BioTherapeutics, Inc. free cash flow was −$13.6M for FY2025, down 284.4% year-over-year. On a trailing twelve-month (TTM) basis, free cash flow stands at $14.6M.

PLX free cash flowPLX FCFPLX FCF 2025PLX free cash flow TTM

▸ Source: FMP /cash-flow-statement · US GAAP · Protalix BioTherapeutics, Inc. · Protalix BioTherapeutics, Inc. SEC 10-K & 10-Q filings · US GAAP · Last updated: Jun 9, 2026